Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
DISEASE(S): Colon Cancer,Colorectal Neoplasms,Rectal Cancer
PROVIDER: 14404 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA